Mark Baum
Chief Executive Officer at HARROW, INC.
Net worth: 28 M $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| R. Brdar | M | 64 | 10 years | |
| Timothy Burns | M | 49 | 11 years | |
| Richard Lindstrom | M | 76 |
Surface Ophthalmics, Inc.
 Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 10 years |
| Adrienne Graves | M | 69 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 6 years |
| Larry Dillaha | M | 60 |
Melt Pharmaceuticals, Inc.
 Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | 3 years |
| Norbert Riedel | M | 66 | 7 years | |
| Michael Turmelle | M | 65 | 7 years | |
| Andrew Livingston | M | - |
Visionology, Inc.
| - |
| Perry J. Sternberg | M | 55 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 2 years |
| Andrew Boll | M | 41 | 13 years | |
| Sean Brynjelsen | M | 52 | 7 years | |
| Jamie Webb | M | - | - | |
| Kim Barratt | M | - | 2 years | |
| Marty Makary | M | 53 | 2 years | |
| Jenn Adams | F | - | 3 years | |
| Scott Grossenbach | M | - | 6 years | |
| David Krempa | M | 35 | 7 years | |
| Charles Casamento | M | 78 | 7 years | |
| Kamran Hosseini | M | 59 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Louis C. Drapeau | M | 79 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Teresa Sparks | F | 55 | 4 years | |
| J. Corley | M | 68 |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 5 years |
| Paul Maier | M | 76 | 7 years | |
| D. Osborne | M | 45 |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | 2 years |
| Giovanni de Castro | M | - |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | 3 years |
| Lauren Silvernail | F | 65 | - | |
| Mark Mannebach | M | - | 1 years | |
| Shelley Thunen | F | 72 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 4 years |
| Dennis E. Saadeh | M | - | - | |
| John Saharek | M | 64 | 12 years | |
| John Berdahl | M | - |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | - |
| Melissa Bradford-Klug | F | - |
Mayfield Pharmaceuticals, Inc.
 Mayfield Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Harrow, Inc., Mayfield Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical products. The company is based in Las Vegas, NV. The CEO of the company is Melissa Bradford-Klug. | - |
| C. Adair | M | - |
Mayfield Pharmaceuticals, Inc.
Mayfield Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Harrow, Inc., Mayfield Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical products. The company is based in Las Vegas, NV. The CEO of the company is Melissa Bradford-Klug. | 5 years |
| Arthur Laffer | M | 83 |
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Luis James Leung | M | 55 |
Audiostocks, Inc.
 Audiostocks, Inc. Data Processing ServicesTechnology Services Audio Stocks, Inc. distributes and makes functional and financial services. It is an internet based publishing platform designed to compile, catalogue, distribute and make functional, financial content and data related to that content. The firm's content is distributed online to individual investors and finance professionals including North American buy-side analysts, investment research professionals and portfolio managers. The company was founded in January, 2002 and is headquartered in Carlsbad, CA.
PNG Ventures, Inc.
 PNG Ventures, Inc. Financial ConglomeratesFinance PNG Ventures, Inc. is a developmental stage company and operates through the subsidiaries. The company's business strategy is to capitalize on the consumption of natural gas, and in particular LNG. The company was founded in 1995 and is headquartered in Dallas, TX. | 3 years |
| Brad Matthew Bingham | M | 46 | 4 years | |
| Lon Bell | M | 83 | 8 years | |
| James B. Panther | M | 51 |
Audiostocks, Inc.
Audiostocks, Inc. Data Processing ServicesTechnology Services Audio Stocks, Inc. distributes and makes functional and financial services. It is an internet based publishing platform designed to compile, catalogue, distribute and make functional, financial content and data related to that content. The firm's content is distributed online to individual investors and finance professionals including North American buy-side analysts, investment research professionals and portfolio managers. The company was founded in January, 2002 and is headquartered in Carlsbad, CA. | - |
| Paul A. Bundschuh | M | 63 | 6 years | |
| Wilson Troutman | M | 69 | 5 years | |
| Robert J. Kammer | M | 74 | 16 years | |
| Marshall Khine | M | 51 |
California Western School of Law
| 3 years |
| Balbir S. Brar | M | 87 | 3 years | |
| David B. Eisenhaure | M | 78 | 8 years | |
| John N. Bonfiglio | M | 69 | 1 years | |
| Kevin W. Markey | M | 64 |
PNG Ventures, Inc.
PNG Ventures, Inc. Financial ConglomeratesFinance PNG Ventures, Inc. is a developmental stage company and operates through the subsidiaries. The company's business strategy is to capitalize on the consumption of natural gas, and in particular LNG. The company was founded in 1995 and is headquartered in Dallas, TX. | 2 years |
| John T. Lomoro | M | 54 | - | |
| Tim Thayne | M | - | - | |
| Jeffrey J. Abrams | M | 76 | 6 years | |
| Jeannette V. Filippone | F | - | 1 years | |
| Rolf Harms | M | - | - | |
| Victor Hollander | M | 91 | - | |
| W. Richard Ferguson | M | - | 1 years | |
| William H. Nelson | M | 78 | 2 years | |
| Darren L. Miles | M | 65 | 2 years | |
| Dean H. Becker | M | - | - | |
| Robert Thele | M | - | - | |
| Paul W. Finnegan | M | 63 | 1 years | |
| Peter Kenny | M | 65 | 1 years | |
| Anthony Principi | M | 80 | 5 years | |
| R. van Horn | M | 56 | 3 years | |
| Stephen G. Austin | M | 71 | 8 years | |
| Juliet Singh | M | 64 | 5 years | |
| August Shelby Bassani | M | 51 | 3 years | |
| Gary Mintz | M | - |
California Western School of Law
| 2 years |
| Roland Fryer | M | - |
The University of Texas at Arlington
| 3 years |
| Allison Hushek | F | - |
California Western School of Law
| 3 years |
| Jon Patton | M | - | 3 years | |
| David Moufarrege | M | - | 2 years | |
| Fred P. Buckingham | M | - |
The University of Texas at Arlington
| 3 years |
| Clayton D. Edwards | M | 56 | 1 years | |
| Roberto Coronado | M | - |
The University of Texas at Arlington
| 4 years |
| David S. Hunt | M | 55 |
California Western School of Law
| 1 years |
| Todd J. Eastman | M | - |
California Western School of Law
| 3 years |
| Kevin Smith | M | - |
The University of Texas at Arlington
| 2 years |
| James D. Clem | M | 48 |
The University of Texas at Arlington
| 4 years |
| Joe Bitterman | M | - | - | |
| Will Boyd | M | - |
The University of Texas at Arlington
| 4 years |
| Chainarong Nimmantevin | M | 56 |
The University of Texas at Arlington
| 2 years |
| Adam Eugene Auten | M | - |
The University of Texas at Arlington
| 5 years |
| Bruce M. Peterson | M | - | - | |
| Lynn Swann | M | 72 | 3 years | |
| James R. Simpson | M | 55 |
California Western School of Law
| 3 years |
| Dane Andreeff | M | 58 |
The University of Texas at Arlington
| 2 years |
| Lee Joshua Eikov | M | - | - | |
| Jeffrey Fisher | M | 60 |
The University of Texas at Arlington
| 2 years |
| Joachim P. H. Schupp | M | 71 | - | |
| Anthony Thornley | M | 77 | 4 years | |
| Terry M. Nida | M | - | 1 years | |
| M. Shawn Gault | M | - |
The University of Texas at Arlington
| 4 years |
| Rashid Sharipov | M | 56 |
California Western School of Law
| 3 years |
| Doug Rollwitz | M | - |
The University of Texas at Arlington
| 2 years |
| Tracy C. Caswell | F | - |
California Western School of Law
| 3 years |
| Jerry Warnick | M | - | - | |
| David I. Davis | M | - | - | |
| Heiner Dreismann | M | 69 | 2 years | |
| Alfred G. Howell | M | - |
California Western School of Law
| 3 years |
| Anthony Horton | M | 63 |
The University of Texas at Arlington
| 1 years |
| Brad Crawford | M | - | - | |
| Andrew Heinz | M | - |
The University of Texas at Arlington
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Baum
- Personal Network
